LIDCO GROUP PLC

("LiDCO" or the "Company" or "the Group")

 AGM Statement

LiDCO (AIM: LID), the hemodynamic monitoring company, will hold its Annual General Meeting today at 11am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ. At the meeting the Chief Executive, Matt Sassone, will make the following statement:

I am pleased to confirm that we continue to make good progress with the strategy laid out in October last year. Sales in the first quarter of the year shows good growth over the comparative period and, as outlined with our results, we expect 2016/17 to be a year of sales growth and cash generation.

Since the start of the financial year I have been able to announce the launch of our new LiDCOunity product, renewal of UK sales distribution contract with Argon Medical, registration of our products in China and the signing of a number of new distribution agreements around the world including in the USA where ICU Medical will sell our LiDCO IM non-invasive hemodynamic monitoring system. In addition, I am pleased to announce that this week we will be launching our non-invasive offering in Japan at the Annual Japanese Society of Anaesthesia meeting. Japan is the second largest hemodynamic monitoring market globally, launching LiDCOrapid with CNAP gives LiDCO increased product differentiation as we look to gain greater market share in this important market.

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:

·    early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·    quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BIS^TM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BIS^TM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP^TM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.